GSK RSV vaccine shows potential to help protect broader group of adults
24th Oct 2024 08:43
(Sharecast News) - Drugmaker GSK said on Thursday that new data for its respiratory syncytial virus vaccine showed potential to help protect a broader group of adults at increased risk for RSV disease.
Read moreGSK UTI treatment gets FDA priority review status
16th Oct 2024 07:20
(Sharecast News) - GSK announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for gepotidacin, a first-in-class oral antibiotic, under priority review.
Read moreGSK reports positive results from depemokimab trial
14th Oct 2024 07:55
(Sharecast News) - GSK has announced positive results from a phase III trial of its depemokimab treatment for chronic rhinosinusitis with nasal polyps (CRSwNP).
Read moreLondon close: Stocks red as US inflation, jobless claims top forecasts
10th Oct 2024 14:58
(Sharecast News) - London's stock markets ended Thursday in negative territory as investors weighed a higher-than-expected inflation and jobless claims readings out of the United States.
Read moreLondon midday: Stocks dip ahead of US inflation reading
10th Oct 2024 12:10
(Sharecast News) - London stocks had fallen into the red by lunchtime on Thursday, as investors awaited crucial US inflation data, which could influence the Federal Reserve's next policy moves.
Read moreGSK's Zantac settlement should give stock a boost, says Jefferies
10th Oct 2024 10:25
(Sharecast News) - GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according to Jefferies, which said the announcement should remove a significant weight on the share price.
Read moreGSK to pay $2.2bn to settle Zantac lawsuits
10th Oct 2024 07:37
(Sharecast News) - GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US.
Read moreGSK's Arexvy provides protection over three RSV seasons, trial shows
8th Oct 2024 11:57
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
Read moreGSK meningococcal vaccine receives EMA recommendation
24th Sep 2024 09:46
(Sharecast News) - Pharmaceutical and biotechnology company GSK said on Tuesday that the European Medicine Agency has recommended meningococcal vaccine for use against certain bacteria groups.
Read moreGSK settles two Zantac cases in California
18th Sep 2024 13:30
(Sharecast News) - GSK announced on Wednesday that it has reached confidential settlements in two lawsuits filed in California State Court related to its discontinued heartburn medication, 'Zantac', or ranitidine.
Read moreJapan to review GSK's Blenrep drug application
17th Sep 2024 07:12
(Sharecast News) - Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.
Read moreLondon close: Stocks finish firmer in subdued trading
13th Sep 2024 16:44
(Sharecast News) - London stocks closed in positive territory on Friday, bolstered by hopes of an interest rate cut in the United States, although the gains were modest as trading remained subdued.
Read moreGSK to speed up development of blood cancer treatment in China
13th Sep 2024 07:19
(Sharecast News) - China's health authority has granted GSK's Blenrep blood cancer treatment with a so-called 'Breakthrough Therapy Designation' (BTD), which is designed to speed up development of investigational drugs.
Read moreGSK reports positive results from mRNA flu vaccine trial
12th Sep 2024 08:55
(Sharecast News) - GSK announced promising results from its phase two clinical trial for an mRNA-based seasonal flu vaccine on Thursday.
Read moreGSK's herpes vaccine candidate fails to meet primary efficacy objective
11th Sep 2024 08:47
(Sharecast News) - Drugmaker GSK said on Wednesday that primary objective data analysts from a phase II trial of its early-stage therapeutic herpes simplex virus vaccine candidate showed that the drug had failed to meet its primary efficacy objective.
Read more